Search for: "Labelle v. State"
Results 801 - 820
of 8,153
Sorted by Relevance
|
Sort by Date
21 Sep 2015, 10:27 am
Brown v. [read post]
21 Sep 2015, 10:27 am
Brown v. [read post]
10 Jul 2012, 4:59 am
Delacruz v. [read post]
19 Mar 2015, 6:00 am
Michigan v Duke, Michigan State v. [read post]
27 Feb 2008, 10:52 am
In LaFace v. [read post]
16 Sep 2020, 9:58 am
Maffick v. [read post]
26 Dec 2011, 4:30 am
In Fisher v. [read post]
31 Jul 2009, 12:29 am
The Court has reversed itself and has stated now that it will direct liability in favor of plaintiffs in SONY BMG Music Entertainment v. [read post]
26 Sep 2022, 6:19 am
The court, reversing the injunction and ruling against the trademark holder, found that the RISE label was a weak trademark because it strongly suggested the qualities of the product it labeled and there was extensive third-party usage of the same or similar marks (RiseandShine Corp. v. [read post]
2 Oct 2022, 9:00 pm
The case, known as Delaware v. [read post]
10 Feb 2015, 1:01 pm
Many states have legislation on the books that insulates non-manufacturing intermediate sellers from strict liability. [read post]
25 May 2007, 7:42 am
Static Control Components, Inc. v. [read post]
7 Oct 2008, 11:33 pm
Following the Ninth Circuit's decision in United States v. [read post]
25 Apr 2011, 2:26 pm
State Bar of California, Rust v. [read post]
6 Aug 2008, 10:03 am
In the Celexa/ Lexapro MDL, the court denied without prejudice the defendant’s preemption motion, to allow further discovery and expressly because the United States Supreme Court has granted certiorari in Levine v. [read post]
14 Jun 2007, 3:32 am
In Arista v. [read post]
24 Mar 2009, 7:00 am
Levine V. [read post]
4 Sep 2020, 10:21 am
” Other Claims The state dilution claim survived because Adler alleged enough in-state fame. [read post]
6 Oct 2010, 1:08 pm
Sullivan, where the Court pierced the “label” attached to the “libelous” speech and considered the balancing factors set forth above. [read post]
30 Apr 2015, 1:11 pm
Levine, 555 U.S. 555 (2009), decision for its holding that there was no “impossibility preemption” – preemption because it was impossible to comply with both state and federal requirements – in the absence of “clear evidence that the FDA would not have approved” the label change the plaintiffs sought. [read post]
